Injectable Extended-Release Naltrexone Disclosures & CME Credit

Neither the case presenter nor the didactic presenter have conflicts of interest.

Off-label use of medications may be discussed.

Project ECHO is supported through funding from the SC State Targeted Response Grant (MUSC-STR-17) through the 21st Century Cures Act (TI080221).

The Medical University of South Carolina designates this live activity for a maximum of 1.0 MAPRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Medical University of South Carolina is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

In accordance with the ACCME Essentials & Standards, anyone involved in planning or presenting this educational activity will be required to disclose any relevant financial relationships with commercial interests in the healthcare industry. This information is listed below. Speakers who incorporate information about off-label or investigational use of drugs or devices will be asked to disclose that information at the beginning of their presentation. Off-label use of naltrexone will be discussed and noted during the presentation.

Naltrexone Indications

Competitive antagonist at the mu opioid receptor and to a lesser extent at the delta and kappa opioid receptors.

High affinity for receptor prevents the binding of opioid agonists and displaces agonists if they are present. Volpicelli et al. Alc Health Res World. 1994;18:273.

Naltrexone Dosing

Oral Naltrexone for OUD Not Recommended

Cochrane review of 13 studies (1158 participants) compared naltrexone to placebo or no pharmacological treatment.

No statistically significant difference in treatment retention or preventing return to opioid use.
Poor adherence is a significant challenge

Oral use limited to:
Highly motivated, e.g. legally mandated to treatment
Aware of negative consequences of nonadherence
Observed dosing
Want to be on antagonist but unwilling or unable to take IMMinozzi et al. Cochrane Database Syst Rev.2011 Feb 16;(2):CD001333

Duration
No recommended length of treatment with naltrexone.

Treatment less than 90 days is of limited effectiveness, and treatment lasting significantly longer is associated with more positive long-term outcomes.

Duration depends on patient response, clinical judgment & the patient’s individual circumstances.
Can be stopped abruptly without withdrawal symptoms.

Contraindications

1. Hypersensitivity reactions to naltrexone or previous hypersensitivity reactions to polylactide-co-glycolide carboxymethylcellulose, or any other constituent of the diluent
2. Active hepatitis (LFTs > 3x normal) or liver failure
3. Patients currently physically dependent on opioids, including partial agonists
4. Patients receiving opioid analgesics
5. Patients in acute opioid withdrawal
6. Failed naloxone challenge or UDS + for opioids

Administer IM with caution to patients with thrombocytopenia or a coagulation disorder

Cautions
1. Loss of tolerance.

2. Hepatic injury is a concern if very high doses are used, for example, 200–300 mg per day.

3. Transient, asymptomatic ↑ transaminases were also observed in the clinical trials & postmarketing period.

4. Patients with co-occurring psychiatric disorders should be monitored for adverse events. Suicidal thoughts, attempted suicide, and depression have been reported.

5. Glyburide may increase serum concentration of naltrexone. Monitor for increased toxicity effects of naltrexone (e.g. liver LFTs). Metabolism

First pass metabolism in liver to 6β-naltrexol, a less potent μ antagonist with a longer duration of action

Elimination half-life:

Oral naltrexone 4 hours
6 β-naltrexol 14 hours

XR-NTX and 6β-naltrexol t ½ 5-10 days depending on erosion of the polymer followed primarily by renal excretion

Russian Multisite Double-Blind, Placebo-Controlled Randomized Trial XR-NTX Chart

Description automatically generated

% of cumulative opioid free weeks

p=.0002

Mean change from baseline craving

Outpatient Noninferiority Trial

12 week multisite open-label RCT in Norway

Following detoxification on detox unit randomized to:

Daily buprenorphine-naloxone 4-24mg (n=79)

Or XR-NTX 380mg IM every 4 weeks (n=80) Retention was non-inferior in ER-NTX vs. bup/nlx (p=.04)

ER-NTX ~70 days vs. bup/nlx ~ 64 days (p=.33)

Total opioid-negative UDSs noninferior

With superiority in lower use of heroin and other opioids (p=.001)


Comparison SL Buprenorphine-Naloxone vs Extended-Release Naltrexone (X:BOT)

Multisite, randomized, open label, controlled 6-month trial

Sublingual buprenorphine-naloxone, 8-24mg (N = 287)

Extended-release injection naltrexone (N = 283) Participants

OUD, Admitted to inpatient/residential treatment Randomized as soon as possible after admission
For injection opioid detoxification had to be completed, urine negative for opioids, and pass naloxone challenge: “induction hurdle” Lee et al. Lancet 2018;391:309-318X-BOT: Relapse-free Survival & Treatment Effect over Time

Lee et al. Lancet 2018;391:309-318

XR-NTX had substantial induction hurdle: XR-NTX 72% vs. BUP-NTX 94%
Among those successfully inducted relapse rates were similar (p=.44)

Intent to Treat Population

Per ProtocolLee et al. Lancet 2018;391:309-318

X-BOT Opioid Craving

p=.001

p=0.2

Initiation to Avoid Precipitated Withdrawal
No or low opioid tolerance (post residential treatment or incarceration) could potentially start immediately pending negative UDS and COWS

Short-acting opioids: off about 6 days before starting naltrexone
Long-acting opioids: such as methadone and buprenorphine off opioids for typically 7–10 days or in some cases14 days

Naloxone or Naltrexone Challenge Test with recent useIM Administration

Needle
Needle

Adverse Reactions

≥ 5% & 2x more frequent than placebo

Nausea or vomiting

Injection site reactions (induration, nodules, swelling, pruritis) To minimize in obese patients use the provided longer needle and avoid SC admin

Decreased appetite or anorexia

Muscle cramps

Sedation

Dizziness or syncope ≥ 2% & 2x more frequent than placebo: abnormal LFTs, injection site pain, nasopharyngitis, injection site pain, & toothache

Postmarketing: additional injection site rxns included induration, cellulitis, hematoma abscess & necrosis. Some cases requiring surgical debridement

Rare: eosinophilic pneumonia, hypersensitivity rxn

Apart from opioids, it does not typically interact with other meds

Hepatoxicity

Historically commonly recommended to monitor patient’s liver function (i.e., AST, ALT, GGT and bilirubin) at baseline and periodically

Hepatoxicity typically seen at oral doses closer to 300mg

Has not been problematic with daily oral naltrexone 50 mg or with the extended-release formulation and has been safely used in patients with liver disease, hepatitis C and HIV.

Current recommendation: not necessary to obtain baseline LFTs or routinely monitor LFTs. (SAMSHA 2016)


Alcohol Dependence

Suicidal events 1% in Vivitrol group vs. 0% in placebo group

In 24-week RCT trial (n=624) depressed mood reported in 10% of XR-NTX compared to 5% in placebo group Garbutt et al. 2005

Opioid Dependence

Open-label US safety study 5% in Vivitrol (n=101) vs. 10% in oral naltrexone group (n=22)

In 24-week Russian RCT (n=250) no depressive or suicidal AEs in either groupKrupitsky et al. 2011

Pregnancy and Breastfeeding

Naltrexone and the 6-beta-naltrexol metabolite cross the placenta. Insufficient research on the safety and efficacy of naltrexone during pregnancy.

If a woman becomes pregnant while she is receiving naltrexone, it may be appropriate to discontinue if the patient and clinician agree that the risk of relapse is low.

If the patient chooses to discontinue naltrexone and is at risk for relapse, treatment with methadone or buprenorphine should be considered.

Insufficient research exists on the risks (if any) of naltrexone for breastfeeding infants. Limited data indicates that naltrexone is minimally excreted into breastmilk

Stroller

Surgery

Oral naltrexone should be discontinued 72 hours before surgery.

XR-NTX should be discontinued 30 days before an anticipated surgery with use of oral naltrexone until 72 hours prior to surgery. Transition from Naltrexone to Buprenorphine or Methadone
Patients will not have physical dependence on opioids and thus the initial doses of methadone or buprenorphine should be low.

Should not be transitioned until a significant amount of the naltrexone is no longer in their system, about 1 day for oral naltrexone or 28 days for XR-NTX.

Long-Acting Naltrexone Induction w Low Dose Naltrexone vs. Buprenorphine

Protocol Day

Naltrexone-assisted detox

Buprenorphine-assisted detox

1

Ancillary meds

2

Buprenorphine 4mg sl BID

3

washout

Buprenorphine 6mg

4

Naltrexone 1mg

Buprenorphine 4mg

5
Naltrexone 3mg

Buprenorphine 4mg

6

Naltrexone 12mg

Buprenorphine 2mg

7

Naltrexone 25mg

Buprenorphine 1mg

8

Extended-release naltrexone 380mg

15

Extended-release naltrexone 380mg

Ancillary meds offered
- clonidine 0.1mg QID
(+Q4HR PRN max 1.2mg)
- clonazepam 0.5mg QID
- prochlorperazine 10mg TID
- trazodone 100mg HS
- zolpidem 10mg HS

Long-Acting Naltrexone Induction w Low Dose Naltrexone vs. Buprenorphine

Protocol Day

Naltrexone-assisted detox

Buprenorphine-assisted detox

Completed

Induction

n=55 (56.1%)

n=17 (32.7%)

Completed trial (wk. 5)

n=51 (52%)

n=15 (28.8%)

2nd injection

n=49 (50%)

n=14 (26.9%)


Crush naltrexone 50mg tabs and mix in water or orange juice

Refrigerated maintains stability for 90 days
Can taste bitter and gritty

For example, 2 tabs of naltrexone 50mg (100mg) crushed and dissolved in 100mg of orange juice = 1mg/ml solution


Oral: ~ $25 for 30 tabs of naltrexone 50mg

Vivitrol: ~ $1,400 excluding cost of visit

Covered by SOR funds

Alkermes patient assistance (up to $500 co-pay or deductible)

https://www.vivitrol.com/co-pay-savings-program

Pharmaceutical grade refrigerator to store

Can store at room temp (not above 77 °F) up to 7 days

Ability to give injections

Biomedical Waste

Have you been abstaining from other opiates & illegal drugs such as cocaine and speed?

2. Do you think you are able to cope with difficult situations without using drugs?

3. Are you employed or in school?

4. Are you staying away from contact with users & illegal activities?

5. Have you gotten rid of your drug paraphernalia?

6. Are you living in a neighborhood that doesn’t have a lot of drug use & are you comfortable there?
7. Are you living in stable family neighborhood?

8. Do you have straight (non-user friends) that you spend time with? CSAT 1994

9. Do you have friends or family that would be helpful during a taper?

10. Have you been participating in counseling that has been helpful?

11. Does your counselor think you are ready to taper?

12. Do you think you would ask for help when you are feeling bad during a taper?

13. Have you been stabilized on buprenorphine?

14. Have you been on buprenorphine for a long time?

15. Are you in good mental and physical health?


XR-Naltrexone: A Step-by-Step Guide


Vivitrol REMS and Patient Medication Guide

https://www.vivitrol.com/content/pdfs/medication-guide.pdf

https://www.vivitrolrems.com/
Printable Wallet Card
https://www.vivitrol.com/content/pdfs/emergency-pain-management-card.pdf
pcssnow.org
Questions and Comments?

hartwelk@musc.edu

MUSC designates this live activity for a maximum of 1.0AMA PRA Category 1 Credit(s)™
MUSC will award 0.1 CEUs for this activity (1 contact hour = 0.1 CEU)

CMEs and CEUs1stand 3rdFRIDAY of each month
12:00 –1:00 pm
10/16/20

Panel: TeleMAT Troubling Shooting During Covid-19

Panel Discussion
New Module
High Quality Medicated Assisted Treatment (MAT)
November 2020 –February 2021
11/6/20

What is High Quality MAT

Dr. Kelly Barth
11/20/20

Screening and SBIRT
Motivation Interviewing

Dr. Elizabeth Santa Ana
12/18/20

MAT in Primary Care: Med Management from POATS

Dr. Michael Capata